Accepted for Publication: May 11, 2015.
Published Online: July 6, 2015. doi:10.1001/jamaneurol.2015.1285.
Study concept and design: Sutphen, Holtzman, Fagan.
Acquisition, analysis, or interpretation of data: Sutphen, Jasielec, Shah, Macy, Xiong, Vlassenko, Benzinger, Stoops, Vanderstichele, Brix, Darby, Vandijck, Ladenson, Morris, Fagan.
Drafting of the manuscript: Sutphen, Fagan.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Jasielec, Xiong.
Obtained funding: Benzinger, Morris, Holtzman.
Administrative, technical, or material support: Shah, Stoops, Vanderstichele, Brix, Darby, Vandijck, Ladenson.
Study supervision: Xiong, Fagan.
Conflict of Interest Disclosures: Dr Benzinger reported being a member of the advisory board for Eli Lilly and Co (2011); receiving research funding from Avid Radiopharmaceuticals; providing expert testimony and receiving compensation from Kujawaski and Associates (2011); and participating in clinical trials sponsored by Eli Lilly and Co, Avid Radiopharmaceuticals, and Roche. Mr Stoops reported being a shareholder of ADx NeuroSciences and BioMARIC NV. Dr Vanderstichele reported being a cofounder and shareholder of ADx NeuroSciences and founder of Biomarkable bvba. Dr Ladenson reported being named on patents related to use of VILIP-1; these are being managed by Washington University in accordance with university policy. Dr Morris reported having participated in or currently participating in clinical trials of antidementia drugs sponsored by Janssen Immunotherapy, Pfizer, Eli Lilly and Co/Avid Radiopharmaceuticals, SNIFF (Study of Nasal Insulin to Fight Forgetfulness), and A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) and serving as a consultant for Lilly USA, ISIS Pharmaceuticals, and the Charles Dana Foundation. Dr Holtzman reported being a cofounder of C2N Diagnostics LLC; serving on the scientific advisory boards of AstraZeneca, Genentech, Neurophage, and C2N Diagnostics; and serving as a consultant for Eli Lilly and Co. Washington University receives grants to the laboratory of Dr Holtzman from the Tau Consortium, Cure Alzheimer’s Fund, the JPB Foundation, Eli Lilly and Co, Janssen, and C2N Diagnostics. Dr Fagan reported serving on the scientific advisory boards of IBL International and Roche and serving as a consultant for AbbVie and Novartis. No other disclosures were reported.
Funding/Support: This work was supported by grants P01AG026276 (Dr Morris), 5P30 NS048056 (Dr Benzinger), and 5P30 NS048056 (Dr Benzinger) from the National Institutes of Health, the Barnes-Jewish Hospital Foundation (Dr Morris), the Fred Simmons and Olga Mohan fund (Dr Morris), and a grant from Eli Lilly and Co (Dr Holtzman).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Genotyping of APOE was performed under the direction of Alison Goate, DPhil, Genetics Core, Knight Alzheimer’s Disease Research Center, Washington University, St Louis, Missouri; she received no compensation. Matthew Amos, Elizabeth Grant, PhD, and Sushila Sathyan, MA, Knight Alzheimer’s Disease Research Center, Washington University, provided technical support; they received no compensation. We acknowledge the contributions of the ACS Administration, Clinical, Biomarker, Imaging, and Biostatistics Cores at the Knight Alzheimer’s Disease Research Center. We gratefully acknowledge the altruism of the ACS participants and their families.